Azul S.A. AZUL posted impressive traffic numbers for the month of June compared with May levels, as air-travel demand picks up on increased inoculation programs.Consolidated traffic, measured in revenue passenger kilometers, increased 18.2% month over month. With travel demand rising, the company expanded capacity significantly. Capacity measured in available seat kilometers moved up 16.8% in June from May levels. Since traffic surge was more than capacity expansion, load factor (% of seats filled by passengers) rose to 76.8% in June from 75.8% in May.On a year-over-year basis (as the current year situation is somewhat better with the coming of vaccines), the scenario was rosier with consolidated traffic surging 280.4%. In the same time frame, capacity expanded 273.4%. Consequently, with traffic surge outweighing capacity expansion, load factor increased 1.4 percentage points (p.p).In the domestic front, traffic and capacity increased 328.2% and 310.9%, respectively, from the year-ago period’s levels. Consequently, load factor increased 3.2 p.p to 78.8% in June. Internationally, in the same time frame, traffic and capacity surged 21.2% and 73.4%, respectively. However, internationally load factor dropped 22.3 p.p to 52%.Compared with June 2019 (pre-COVID) levels, both traffic and capacity plunged 24% and 17.3%, respectively. Moreover, the load factor also tanked 6.8 p.p to 83.6% as decline in traffic was more than capacity contraction.Zacks Rank & Stocks to ConsiderAzul currently carries a Zacks Rank #5 (Strong Sell).Some better-ranked stocks in the broader Zacks Transportation sector are Landstar System LSTR, C.H. Robinson CHRW and FedEx Corporation FDX. Landstar and C.H. Robinson carry a Zacks Rank #2 (Buy), while FedEx sports a Zacks #1(Strong Buy) Rank. You can see the complete list of today’s Zacks #1 Rank stocks here.Long-term (three to five years) expected earnings per share growth rate for Landstar, C.H. Robinson and FedEx is projected at 12%, 9% and 12%, respectively. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report C.H. Robinson Worldwide, Inc. (CHRW): Free Stock Analysis Report FedEx Corporation (FDX): Free Stock Analysis Report Landstar System, Inc. (LSTR): Free Stock Analysis Report AZUL SA (AZUL): Free Stock Analysis Report To read this article on Zacks.com click here.